Lyphe Dispensary has expanded its Noidecs V range, offering high-quality medical cannabis products that are both affordable and tailored to patient preferences.
Following the June 2024 launch of Noidecs Vital Platinum OG, the new collection adds four products: VOne, VTwo, VThree, and VFour. These options simplify the patient experience by providing a tiered THC approach.
VOne caters to beginners or those seeking mild relief, while VFour offers higher THC levels for experienced users. The range enables patients to select products best suited to their therapeutic requirements, maintaining affordability throughout.
“Patients are advocating for lower cost, yet sustainable options, and we want them to know that Lyphe is not only listening but taking action,” said Hayley Thompson, Managing Director at Lyphe Clinic. “The Noidecs VOne-VFour line aims to bridge the gap between quality and cost, offering patients a reliable and accessible option for managing their health conditions.”
This expanded range reflects Lyphe’s mission to provide cost-effective, high-quality medical cannabis, made possible by economies of scale and streamlined supply chains.
Changes in MHRA’s no objection letter guidelines mean the “Vital” branding will evolve, but its core principles remain unchanged.
Noidecs VThree launches in Winter 2024, with the full line expected in early 2025. Further updates will be provided in due course.
